Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 99 results for bevacizumab

  1. Exploratory work regarding the use of bevacizumab in the treatment of eye conditions [ID422]

    Discontinued Reference number: GID-TA11205

    Technology appraisal guidance
    Discontinued

  2. Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

    This guidance has been updated and replaced by NICE's technology appraisal guidance on bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136).

    Withdrawn guidance

  3. Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (TA724)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.

    Technology appraisal guidance
    Published
    8 September 2021
    View recommendations

    Sections for TA724

  4. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

    Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.

    Technology appraisal guidance
    Published
    17 October 2018
    View recommendations

    Sections for TA544

  5. Tivozanib for treating advanced renal cell carcinoma (TA512)

    Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    21 March 2018
    View recommendations

    Sections for TA512

  6. Erlotinib in combination with bevacizumab for the maintenance treatment of advanced or metastatic non-small cell lung cancer [ID44]

    Discontinued Reference number: GID-TA11206

    Technology appraisal guidance
    Discontinued

  7. Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

    In development Reference number: GID-TAG406 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Erlotinib in combination with bevacizumab for the second line treatment of advanced or metastatic non-small cell lung cancer [ID43]

    Discontinued Reference number: GID-TA11207

    Technology appraisal guidance
    Discontinued

  9. Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

    In development Reference number: GID-TAG388 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.

    HealthTech guidance
    Published
    10 December 2014
    View recommendations

    Sections for HTG360

  11. Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]

    Discontinued Reference number: GID-TA11074

    Technology appraisal guidance
    Discontinued

  12. Treatments for non-small-cell lung cancer [ID6234]

    Discontinued Reference number: GID-TA11289

    Technology appraisal guidance
    Discontinued

  13. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development Reference number: GID-TA10900 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (TA908)

    Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    5 July 2023
    View recommendations

    Sections for TA908

  15. Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)

    Evidence-based recommendations on pralsetinib (Gavreto) for treating RET fusion-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    3 August 2022
    View recommendations

    Sections for TA812